Although patients with idiopathic pulmonary fibrosis (IPF) who take Ofev (nintedanib) or Esbriet (pirfenidone) have similar clinical outcomes, adherence…
Articles by Patricia Inácio, PhD
A post-hoc analysis of the Phase 3 RECAP trial shows that long-term treatment with Esbriet (pirfenidone) is safe and…
High levels of PD-L1 protein were found in the most aggressive fibroblasts that drive idiopathic pulmonary fibrosis (IPF) progression, making…
Ofev (nintedanib) may exert its therapeutic benefits by halting the activity of genes that promote proliferation of fibroblasts in…
A protein in the tumor necrosis factor (TNF) alpha family, called TRAIL, regulates a signaling cascade that promotes pulmonary fibrosis,…
A protein called cadherin-11 (CDH11) ties together macrophages and myofibroblasts in an “eternal hug” in the lungs of idiopathic…
The tolerability and safety of Ofev (nintedanib) and Esbriet (pirfenidone) treatments in a small group of patients with…
A Phase 1 trial shows that combining Sprycel (dasatinib) with the plant-based flavonoid quercetin improved the physical function…
The nerve injury-induced protein 1 (Ninjurin1, or Ninj1) may contribute to pulmonary fibrosis (PF) by promoting the inflammatory response of immune cells,…
Esbriet (pirfenidone) can improve survival rates of idiopathic pulmonary fibrosis (IPF) patients by 30 percent, a real-world retrospective analysis shows.